Invasive Ductal Breast Cancer with Osteoclast-Like Giant Cells: A Case Report Based on the Gene Expression Profile for Changes in Management
| Autor: | Lia Ginaldi, Massimo De Martinis, Francesca De Pietro, Carlo D'Ugo, Gina Rosaria Quaglione, Maria Maddalena Sirufo, Enrica Maria Bassino, Azzurra Irelli |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty medicine.medical_treatment adjuvant treatment Medicine (miscellaneous) lcsh:Medicine Case Report 03 medical and health sciences 0302 clinical medicine Internal medicine medicine rare breast cancer Neoplastic Nodule Chemotherapy medicine.diagnostic_test business.industry lcsh:R medicine.disease Comorbidity osteoclast-like giant cells Oncotype Dx 030104 developmental biology Giant cell gene profiling 030220 oncology & carcinogenesis Hormone therapy Oncotype DX business Adjuvant Quadrantectomy |
| Zdroj: | Journal of Personalized Medicine, Vol 11, Iss 156, p 156 (2021) Journal of Personalized Medicine |
| ISSN: | 2075-4426 |
| Popis: | We report the case of a 49-year-old woman diagnosed with a rare histotype of early breast cancer (BC), invasive ductal carcinoma with osteoclast-like giant cells (OGCs), from the perspective of gene profile analysis tests. The patient underwent a quadrantectomy of the right breast with removal of 2 cm neoplastic nodule and three ipsilateral sentinel lymph nodes. The Oncotype Dx gave a recurrence score (RS) of 23, and taking into account the patient’s age, an RS of 23 corresponds to a chemotherapy benefit of 6.5%. After a multidisciplinary collegial discussion, and in consideration of the patient’s age, the absence of comorbidity, the premenopausal state, the rare histotype and the Oncotype Dx report, the patient was offered adjuvant chemotherapy treatment followed by hormone therapy. This case may be an example of the utility of integrating gene expression profiling tests into clinical practice in the adjuvant treatment decision of a rare histotype BC. The Oncotype Dx test required to supplement the histological examination made us opt for the proposal of a combined treatment of adjuvant chemotherapy followed by adjuvant hormone therapy. It demonstrates the importance of considering molecular tests and, in particular, the Oncotype Dx, in estimating the risk of disease recovery at 10 years in order to identify patients who benefit from hormone therapy alone versus those who benefit from the addition of chemotherapy, all with a view toward patient-centered oncology. Here, we discuss the possible validity and limitations of the Oncotype Dx in a rare luminal A-like histotype with high infiltrate of stromal/inflammatory cells. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|